{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:31:11Z","timestamp":1786980671959,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Senju","award":["7122Jr-09c"],"award-info":[{"award-number":["7122Jr-09c"]}]},{"DOI":"10.13039\/501100004823","name":"Nagoya University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004823","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study evaluated the clinical outcomes and aqueous humor cytokine levels in eyes with neovascular age-related macular degeneration (nAMD) switched from intravitreal aflibercept to ranibizumab biosimilar (BS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study design<\/jats:title>\n                    <jats:p>Prospective observational study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Thirty-eight eyes of 38 patients with nAMD who received aflibercept under a treat-and-extend (TAE) regimen were prospectively switched to ranibizumab BS. Eight eyes with cataracts undergoing surgery served as controls for aqueous humor cytokine analysis. Best-corrected visual acuity (BCVA) and anatomical outcomes were assessed over one year. The aqueous humor levels of vascular endothelial growth factor (VEGF)-A, angiopoietin-2 (Ang-2), and placental growth factor (PlGF) were measured before and after switching in eyes with nAMD and at surgery in controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Disease activity remained controlled in 94.3% of patients with nAMD for over one year. No significant changes were observed in the BCVA (\n                      <jats:italic>P<\/jats:italic>\n                      =0.65) after one year. Ang-2 levels remained unchanged (\n                      <jats:italic>P<\/jats:italic>\n                      =0.66) and were not significantly different between eyes with nAMD and controls both before (\n                      <jats:italic>P<\/jats:italic>\n                      =0.64) and after switching (\n                      <jats:italic>P<\/jats:italic>\n                      =0.30). PlGF levels also remained stable (\n                      <jats:italic>P<\/jats:italic>\n                      =0.12) but were significantly higher in eyes with nAMD than in controls both before (\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.01) and after switching (\n                      <jats:italic>P<\/jats:italic>\n                      =0.03). VEGF-A levels significantly increased after switching (\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.01) but remained lower than in the controls both before (P&lt;0.01) and after switching (\n                      <jats:italic>P<\/jats:italic>\n                      =0.02).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Switching from aflibercept to ranibizumab BS effectively maintained disease stability and cytokine balance in eyes with nAMD. These findings support ranibizumab BS as a viable and cost-effective alternative for long-term treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10384-025-01224-0","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T23:00:10Z","timestamp":1749682810000},"page":"886-893","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of switching from existing anti-vascular endothelial growth factor drugs to ranibizumab biosimilar in neovascular age-related macular degeneration"],"prefix":"10.1007","volume":"69","author":[{"given":"Hikaru","family":"Ota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Nonogaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji M.","family":"Nishiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"1224_CR1","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/eye.2015.288","volume":"30","author":"A Quartilho","year":"2016","unstructured":"Quartilho A, Simkiss P, Zekite A, Xing W, Wormald R, Bunce C. Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013. Eye. 2016;30:602\u20137.","journal-title":"Eye"},{"key":"1224_CR2","unstructured":"Collaborators G 2019 B and VI, Adelson JD, Bourne RRA, Briant PS, Flaxman SR, Taylor HRB, et al. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the right to sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9:e144\u201360."},{"key":"1224_CR3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.exer.2005.05.007","volume":"82","author":"IA Bhutto","year":"2006","unstructured":"Bhutto IA, McLeod DS, Hasegawa T, Kim SY, Merges C, Tong P, et al. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp Eye Res. 2006;82:99\u2013110.","journal-title":"Exp Eye Res"},{"key":"1224_CR4","doi-asserted-by":"crossref","first-page":"45081","DOI":"10.1038\/srep45081","volume":"7","author":"DS Ng","year":"2017","unstructured":"Ng DS, Yip YW, Bakthavatsalam M, Chen LJ, Ng TK, Lai TY, et al. Elevated angiopoietin 2 in aqueous of patients with neovascular age related macular degeneration correlates with disease severity at presentation. Sci Rep. 2017;7:45081.","journal-title":"Sci Rep"},{"key":"1224_CR5","doi-asserted-by":"crossref","first-page":"10520","DOI":"10.1038\/s41598-018-28484-w","volume":"8","author":"N Terao","year":"2018","unstructured":"Terao N, Koizumi H, Kojima K, Yamagishi T, Yamamoto Y, Yoshii K, et al. Distinct aqueous humour cytokine profiles of patients with pachychoroid neovasculopathy and neovascular age-related macular degeneration. Sci Rep. 2018;8:10520.","journal-title":"Sci Rep"},{"key":"1224_CR6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s10384-018-0623-4","volume":"63","author":"Y Morizane","year":"2019","unstructured":"Morizane Y, Morimoto N, Fujiwara A, Kawasaki R, Yamashita H, Ogura Y, et al. Incidence and causes of visual impairment in Japan: the first nation-wide complete enumeration survey of newly certified visually impaired individuals. Jpn J Ophthalmol. 2019;63:26\u201333.","journal-title":"Jpn J Ophthalmol"},{"key":"1224_CR7","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1007\/s00417-024-06519-5","volume":"262","author":"H Ota","year":"2024","unstructured":"Ota H, Kataoka K, Asai K, Takeuchi J, Nakano Y, Nakamura K, et al. Five-year outcomes of treat and extend regimen using intravitreal aflibercept injection for treatment-na\u00efve age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024;262:3483\u201391.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1224_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/2515841420984586","author":"K Ishibashi","year":"2021","unstructured":"Ishibashi K, Haruta M, Ishibashi Y, Noda R, Dake S, Yoshida S. Four-year outcomes of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a treat-and-extend regimen in Japanese patients. Ther Adv Ophthalmol. 2021. https:\/\/doi.org\/10.1177\/2515841420984586.","journal-title":"Ther Adv Ophthalmol"},{"key":"1224_CR9","first-page":"1350","volume":"28","author":"ZA Siddiqui","year":"2022","unstructured":"Siddiqui ZA, Dhumal T, Patel J, LeMasters T, Almony A, Kamal KM. Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: a budget impact analysis. J Manag Care Spec Pharm. 2022;28:1350\u201364.","journal-title":"J Manag Care Spec Pharm"},{"key":"1224_CR10","doi-asserted-by":"crossref","first-page":"9478","DOI":"10.1167\/iovs.11-8353","volume":"52","author":"KM Ford","year":"2011","unstructured":"Ford KM, Saint-Geniez M, Walshe T, Zahr A, D\u2019Amore PA. Expression and role of VEGF in the adult retinal pigment epithelium. Investig Ophthalmol Vis Sci. 2011;52:9478\u201387.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"1224_CR11","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1172\/JCI65157","volume":"122","author":"T Kurihara","year":"2012","unstructured":"Kurihara T, Westenskow PD, Bravo S, Aguilar E, Friedlander M. Targeted deletion of Vegfa in adult mice induces vision loss. J Clin Investig. 2012;122:4213\u20137.","journal-title":"J Clin Investig"},{"key":"1224_CR12","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1167\/iovs.18-23994","volume":"59","author":"A Nishinaka","year":"2018","unstructured":"Nishinaka A, Inoue Y, Fuma S, Hida Y, Nakamura S, Shimazawa M, et al. Pathophysiological role of VEGF on retinal edema and nonperfused areas in mouse eyes with retinal vein occlusion. Investig Opthalmol Vis Sci. 2018;59:4701\u201313.","journal-title":"Investig Opthalmol Vis Sci."},{"key":"1224_CR13","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","volume":"121","author":"JE Grunwald","year":"2014","unstructured":"Grunwald JE, Daniel E, Huang J, Ying G, Maguire MG, Toth CA, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121:150\u201361.","journal-title":"Ophthalmology"},{"key":"1224_CR14","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/opo.12131","volume":"34","author":"RA Armstrong","year":"2014","unstructured":"Armstrong RA. When to use the Bonferroni correction. Ophthalmic Physiol Opt. 2014;34:502\u20138.","journal-title":"Ophthalmic Physiol Opt"},{"key":"1224_CR15","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/bjophthalmol-2017-310284","volume":"102","author":"S Sakamoto","year":"2018","unstructured":"Sakamoto S, Takahashi H, Tan X, Inoue Y, Nomura Y, Arai Y, et al. Changes in multiple cytokine concentrations in the aqueous humour of neovascular age-related macular degeneration after 2 months of ranibizumab therapy. Br J Ophthalmol. 2018;102:448\u201354.","journal-title":"Br J Ophthalmol"},{"key":"1224_CR16","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ajo.2011.01.027","volume":"152","author":"G Querques","year":"2011","unstructured":"Querques G, Coscas F, Forte R, Massamba N, Sterkers M, Souied EH. Cystoid macular degeneration in exudative age-related macular degeneration. Am J Ophthalmol. 2011;152:100-7.e2.","journal-title":"Am J Ophthalmol"},{"key":"1224_CR17","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41598-018-36704-6","volume":"9","author":"T-T Lai","year":"2019","unstructured":"Lai T-T, Hsieh Y-T, Yang C-M, Ho T-C, Yang C-H. Biomarkers of optical coherence tomography in evaluating the treatment outcomes of neovascular age-related macular degeneration: a real-world study. Sci Rep. 2019;9:529.","journal-title":"Sci Rep"},{"key":"1224_CR18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1136\/bjo-2024-325640","volume":"109","author":"D Zur","year":"2025","unstructured":"Zur D, Guymer R, Korobelnik J-F, Wu L, Viola F, Eter N, et al. Impact of residual retinal fluid on treatment outcomes in neovascular age-related macular degeneration. Br J Ophthalmol. 2025;109:307\u201315.","journal-title":"Br J Ophthalmol"},{"key":"1224_CR19","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s00417-021-05526-0","volume":"260","author":"H Matsubara","year":"2022","unstructured":"Matsubara H, Matsui Y, Miyata R, Ichio A, Chujo S, Enomoto H, et al. Effects of suspension of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration in clinical setting. Graefes Arch Clin Exp Ophthalmol. 2022;260:1867\u201376.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1224_CR20","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.3390\/jcm13154317","volume":"13","author":"S Chujo","year":"2024","unstructured":"Chujo S, Matsubara H, Mase Y, Kato K, Kondo M. Recurrence rate during 5-year period after suspension of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration. J Clin Med. 2024;13:4317.","journal-title":"J Clin Med"},{"key":"1224_CR21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.oret.2017.07.009","volume":"2","author":"SD Adrean","year":"2018","unstructured":"Adrean SD, Chaili S, Grant S, Pirouz A. Recurrence rate of choroidal neovascularization in neovascular age-related macular degeneration managed with a treat\u2013extend\u2013stop protocol. Ophthalmol Retina. 2018;2:225\u201330.","journal-title":"Ophthalmol Retina."},{"key":"1224_CR22","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.2147\/OPTH.S273564","volume":"14","author":"D Bhagat","year":"2020","unstructured":"Bhagat D, Kirby B, Bhatt H, Jager R, George M, Sheth V. Patient preferences associated with anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration and diabetic macular edema. Clin Ophthalmol. 2020;14:2975\u201382.","journal-title":"Clin Ophthalmol"},{"key":"1224_CR23","volume":"17","author":"S Ozdemir","year":"2022","unstructured":"Ozdemir S, Finkelstein E, Lee JJ, Too IHK, Teo KYC, Tan ACS, et al. Understanding patient preferences in anti-VEGF treatment options for age-related macular degeneration. PLoS ONE. 2022;17: e0272301.","journal-title":"PLoS ONE"},{"key":"1224_CR24","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s40123-023-00715-y","volume":"12","author":"Y Yanagi","year":"2023","unstructured":"Yanagi Y, Takahashi K, Iida T, Gomi F, Morii J, Kunikane E, et al. Cost-effectiveness analysis of ranibizumab biosimilar for neovascular age-related macular degeneration in Japan. Ophthalmol Ther. 2023;12:2005\u201321.","journal-title":"Ophthalmol Ther"},{"key":"1224_CR25","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.15252\/emmm.201505889","volume":"8","author":"JT Regula","year":"2016","unstructured":"Regula JT, von Leithner PL, Foxton R, Barathi VA, Cheung CMG, Tun SBB, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. Embo Mol Med. 2016;8:1265\u201388.","journal-title":"Embo Mol Med"},{"key":"1224_CR26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12950-018-0203-x","volume":"15","author":"R Motohashi","year":"2018","unstructured":"Motohashi R, Noma H, Yasuda K, Kotake O, Goto H, Shimura M. Dynamics of soluble vascular endothelial growth factor receptors and their ligands in aqueous humor during ranibizumab for age-related macular degeneration. J Inflamm (Lond). 2018;15:26.","journal-title":"J Inflamm (Lond)"},{"key":"1224_CR27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171\u201385.","journal-title":"Angiogenesis"},{"key":"1224_CR28","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1136\/bjophthalmol-2015-308264","volume":"100","author":"S Fauser","year":"2016","unstructured":"Fauser S, Muether PS. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times. Br J Ophthalmol. 2016;100:1494\u20138.","journal-title":"Br J Ophthalmol"},{"key":"1224_CR29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/ceo.13002","volume":"46","author":"T Sawada","year":"2018","unstructured":"Sawada T, Wang X, Sawada O, Saishin Y, Ohji M. Aqueous vascular endothelial growth factor and aflibercept concentrations after bimonthly intravitreal injections of aflibercept for age-related macular degeneration. Clin Exp Ophthalmol. 2018;46:46\u201353.","journal-title":"Clin Exp Ophthalmol"},{"key":"1224_CR30","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/17425255.2024.2401600","volume":"20","author":"MW Stewart","year":"2024","unstructured":"Stewart MW. Intraocular drugs: pharmacokinetic strategies and the influence on efficacy and durability. Expert Opin Drug Metab Toxicol. 2024;20:977\u201387.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1224_CR31","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","volume":"382","author":"U Chakravarthy","year":"2013","unstructured":"Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382:1258\u201367.","journal-title":"Lancet"},{"key":"1224_CR32","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1097\/IAE.0000000000003207","volume":"41","author":"A Eshtiaghi","year":"2021","unstructured":"Eshtiaghi A, Issa M, Popovic MM, Muni RH, Kertes PJ. Geographic atrophy incidence and progression after intravitreal injections of anti-vascular endothelial growth factor agents for age-related macular degeneration. Retina. 2021;41:2424\u201335.","journal-title":"Retina"},{"key":"1224_CR33","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1097\/IAE.0000000000001862","volume":"38","author":"HJ Cho","year":"2018","unstructured":"Cho HJ, Hwang HJ, Kim HS, Han JI, Lee DW, Kim JW. Intravitreal aflibercept and ranibizumab injections for TYPE 3 neovascularization. Retina. 2018;38:2150\u20138.","journal-title":"Retina"},{"key":"1224_CR34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.oret.2021.03.010","volume":"6","author":"S Aslanis","year":"2022","unstructured":"Aslanis S, Amr\u00e9n U, Lindberg C, Epstein D. Recurrent neovascular age-related macular degeneration after discontinuation of vascular endothelial growth factor inhibitors managed in a treat-and-extend regimen. Ophthalmol Retina. 2022;6:15\u201320.","journal-title":"Ophthalmol Retina."}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01224-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-025-01224-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01224-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:04:36Z","timestamp":1762880676000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-025-01224-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1224"],"URL":"https:\/\/doi.org\/10.1007\/s10384-025-01224-0","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H. Ota, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Novartis, Santen, Bayer, Senju, Chugai); J. Takeuchi, Grants or contracts (AMO), Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Novartis, Santen, Bayer, Senju, Chugai); R. Nonogaki, None; K. Tamura, None; H. Kaneko, Grants or contracts (Senju, AMO), Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Bayer, AMO, Santen, Novartis, HOYA, Alcon, Chugai, Kowa, Nitto Medic, Boehringer Ingelheim, Senju); K. M. Nishiguchi, Grants or contracts (JCR Pharma, Alcon, Bayer, Sumitomo, Santen, Senju, ROHTO, Otsuka, Ritz Medical, Kyouwaika, AMO, HOYA, Wakamoto, Chugai, Janssen), Consulting fees (Novartis, Senju, Janssen, Sysmex), Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Alcon, Bayer, Novartis, Santen, Chugai, Kowa, Senju, Otsuka, Wakamoto, HOYA, AMO, AbbVie, Sumitomo, REGEN BIO, ROHTO, Janssen, Boehringer Ingelheim), Patents planned, issued or pending (WO\/2020\/096049, PCT\/JP2022\/046944, PCT\/JP2023\/006843).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}